<!doctype html>
<body>
<link rel="stylesheet" type="text/css" href="stylesheet.css">
<div class="crocodoc-2jt6Qd crocodoc-page-text" style="width:654.0pt; height:834.0pt;">
<div class="tb f5782 f5765" style="font-size:8pt;letter-spacing:0.56pt;fill:#ffffff;top:761.71pt;left:573.73pt;width:10.03pt;height:9.62pt;"><span class="tx" style="top:0pt;left:0pt;padding-bottom:0.06em;">99</span><br /></div>
<div class="tb f1602 f777" style="font-size:8pt;letter-spacing:0.56pt;fill:#e6910d;top:761.49pt;left:480.99pt;width:77.83pt;height:9.51pt;"><span class="tx" style="top:0pt;left:0pt;padding-bottom:0.06em;">GAME-CHANGERS</span><br /></div>
<div class="tb f1489 f786" style="font-size:10pt;fill:#231f20;top:82.65pt;left:340.5pt;width:240.86pt;height:640.71pt;"><span class="tx" style="top:0pt;left:0pt;padding-bottom:0.38em;">approach in one treatment, may become an important </span><span class="tx" style="top:14pt;left:0pt;padding-bottom:0.38em;padding-right:0.44em;">discipline for disease management, reducing hospital </span><span class="tx" style="top:28pt;left:0pt;padding-bottom:0.38em;padding-right:2em;">costs by accelerating patients&#8217; recovery times and </span><span class="tx" style="top:42pt;left:0pt;padding-bottom:0.38em;padding-right:1.04em;">complications caused by invasive surgery. Advances </span><span class="tx" style="top:56pt;left:0pt;padding-bottom:0.38em;padding-right:1.42em;">in synthetic biology will likely result in production </span><span class="tx" style="top:70pt;left:0pt;padding-bottom:0.38em;padding-right:1.87em;">facilities making novel treatments and diagnostics </span><span class="tx" style="top:84pt;left:0pt;padding-bottom:0.38em;padding-right:1.9em;">agents. Advances in regenerative medicine almost </span><span class="tx" style="top:98pt;left:0pt;padding-bottom:0.38em;">certainly will parallel these developments in diagnostic </span><span class="tx" style="top:112pt;left:0pt;padding-bottom:0.38em;padding-right:1.76em;">and treatment protocols. For example, replacement </span><span class="tx" style="top:126pt;left:0pt;padding-bottom:0.38em;padding-right:0.35em;">organs, such as kidneys and livers, could be developed </span><span class="tx" style="letter-spacing:-0.16pt;word-spacing:0.16pt;top:140pt;left:0pt;padding-bottom:1.78em;padding-right:20.42em;">by 2030.</span><span class="tx" style="top:168pt;left:0pt;padding-bottom:0.38em;padding-right:3.19em;">The new disease management technologies will </span><span class="tx" style="top:182pt;left:0pt;padding-bottom:0.38em;padding-right:0.06em;">increase the longevity and quality of life for the world&#8217;s </span><span class="tx" style="top:196pt;left:0pt;padding-bottom:0.38em;padding-right:2.22em;">aging population, tipping the demographic pro<span style="width:0.58em;">fi</span>le </span><span class="tx" style="top:210pt;left:0pt;padding-bottom:0.38em;padding-right:3.16em;">of many countries toward an older (but healthy) </span><span class="tx" style="top:224pt;left:0pt;padding-bottom:0.38em;padding-right:3.59em;">population. However, improvements in disease </span><span class="tx" style="top:238pt;left:0pt;padding-bottom:0.38em;padding-right:2.01em;">management technologies could be out of reach of </span><span class="tx" style="top:252pt;left:0pt;padding-bottom:0.38em;padding-right:2.94em;">poor people in countries that do not have health </span><span class="tx" style="letter-spacing:-0.11pt;word-spacing:0.11pt;top:266pt;left:0pt;padding-bottom:1.78em;padding-right:17.24em;">coverage for all.</span><span class="tx" style="top:294pt;left:0pt;padding-bottom:0.38em;padding-right:3.89em;">Cost is the major barrier preventing molecular </span><span class="tx" style="top:308pt;left:0pt;padding-bottom:0.38em;padding-right:2.63em;">diagnostic technologies from becoming routinely </span><span class="tx" style="top:322pt;left:0pt;padding-bottom:0.38em;padding-right:3.12em;">available in physician&#8217;s surgeries, although costs </span><span class="tx" style="top:336pt;left:0pt;padding-bottom:0.38em;padding-right:2.12em;">for genetic sequencing are rapidly decreasing. The </span><span class="tx" style="top:350pt;left:0pt;padding-bottom:0.38em;padding-right:1.29em;">cost per individual diagnostic test is more important </span><span class="tx" style="top:364pt;left:0pt;padding-bottom:0.38em;padding-right:2.37em;">than the cost of the diagnostic equipment itself. A </span><span class="tx" style="top:378pt;left:0pt;padding-bottom:0.38em;padding-right:2.66em;">move away from expensive biological reagents to </span><span class="tx" style="letter-spacing:-0.03pt;word-spacing:0.03pt;top:392pt;left:0pt;padding-bottom:0.38em;padding-right:0.37em;">silicon-based molecular diagnostics procedures should </span><span class="tx" style="top:406pt;left:0pt;padding-bottom:0.38em;padding-right:0.08em;">reduce the costs of genetic tests further. The drawback </span><span class="tx" style="top:420pt;left:0pt;padding-bottom:0.38em;padding-right:3.05em;">of today&#8217;s genetic pro<span style="width:0.58em;">fi</span>ling is that the number of </span><span class="tx" style="top:434pt;left:0pt;padding-bottom:0.38em;padding-right:0.78em;">known disease-related genes is insuf<span style="width:0.55em;">fi</span>cient to provide </span><span class="tx" style="top:448pt;left:0pt;padding-bottom:0.38em;padding-right:2.9em;">mass screening. Synergistic technologies such as </span><span class="tx" style="top:462pt;left:0pt;padding-bottom:0.38em;padding-right:1.05em;">computer processing power and big data storage and </span><span class="tx" style="top:476pt;left:0pt;padding-bottom:0.38em;padding-right:2.69em;">analysis will be important for managing the huge </span><span class="tx" style="top:490pt;left:0pt;padding-bottom:0.38em;padding-right:2.54em;">amounts of data gathered by genome sequencing. </span><span class="tx" style="top:504pt;left:0pt;padding-bottom:0.38em;padding-right:1.01em;">However, with computing technology still advancing </span><span class="tx" style="top:518pt;left:0pt;padding-bottom:0.38em;padding-right:3.91em;">at a high rate computer power should not be a </span><span class="tx" style="top:532pt;left:0pt;padding-bottom:0.38em;padding-right:0.96em;">rate-limiting factor. Acquiring governments&#8217; approval </span><span class="tx" style="top:546pt;left:0pt;padding-bottom:0.05em;padding-right:1.65em;">for diagnostic tests will delay their implementation. </span><br /><span class="tx f5782 f5765" style="font-size:9pt;top:577.77pt;left:0pt;padding-bottom:0.06em;">HUMAN AUGMENTATION</span><br /><span class="tx" style="top:602pt;left:0pt;padding-bottom:0.38em;">Spanning a wide gamut of technologies, ranging from </span><span class="tx" style="top:616pt;left:0pt;padding-bottom:0.38em;padding-right:1.21em;">implants and prosthetics to powered exoskeletons, </span><span class="tx" style="top:630pt;left:0pt;padding-bottom:0.05em;">human augmentation enhances innate human abilities, </span><br /></div>
<div class="tb f1489 f786" style="font-size:10pt;fill:#231f20;top:82.65pt;left:75pt;width:240.81pt;height:640.71pt;"><span class="tx" style="top:0pt;left:0pt;padding-bottom:0.38em;">will likely transform everyday life, particularly for the </span><span class="tx" style="top:14pt;left:0pt;padding-bottom:1.78em;padding-right:5.09em;">elderly and mobility-impaired populations.</span><span class="tx" style="top:42pt;left:0pt;padding-bottom:0.38em;padding-right:2.35em;">The greatest gains in healthy longevity are likely </span><span class="tx" style="top:56pt;left:0pt;padding-bottom:0.38em;padding-right:2.61em;">to occur in those developing countries that will </span><span class="tx" style="top:70pt;left:0pt;padding-bottom:0.38em;padding-right:0.45em;">experience a huge growth in the size of their middle </span><span class="tx" style="top:84pt;left:0pt;padding-bottom:0.38em;padding-right:1.02em;">class populations. Although the current health-care </span><span class="tx" style="top:98pt;left:0pt;padding-bottom:0.38em;padding-right:1.19em;">systems of such countries may be poor, developing </span><span class="tx" style="top:112pt;left:0pt;padding-bottom:0.38em;">countries are expected to make substantial progress in </span><span class="tx" style="top:126pt;left:0pt;padding-bottom:0.38em;padding-right:1.1em;">the longevity potential of their populations by 2030. </span><span class="tx" style="top:140pt;left:0pt;padding-bottom:0.38em;padding-right:0.42em;">Indeed, many leading centers of innovation in disease </span><span class="tx" style="top:154pt;left:0pt;padding-bottom:0.05em;padding-right:6.62em;">management are likely to be in the East.</span><br /><span class="tx f5782 f5765" style="font-size:9pt;top:185.77pt;left:0pt;padding-bottom:0.06em;">DISEASE MANAGEMENT</span><br /><span class="tx" style="top:210pt;left:0pt;padding-bottom:0.38em;">Disease management is the effective control and </span><span class="tx" style="letter-spacing:-0.03pt;word-spacing:0.03pt;top:224pt;left:0pt;padding-bottom:0.38em;">treatment of communicable and noncommunicable </span><span class="tx" style="top:238pt;left:0pt;padding-bottom:0.38em;">illnesses. Today, physicians struggle to differentiate </span><span class="tx" style="top:252pt;left:0pt;padding-bottom:0.38em;padding-right:1.47em;">between many illnesses with similar symptoms. </span><span class="tx" style="top:266pt;left:0pt;padding-bottom:0.38em;padding-right:1.92em;">Obtaining results from detection tests can take </span><span class="tx" style="top:280pt;left:0pt;padding-bottom:0.38em;padding-right:0.62em;">several days, leading to delays in diagnosis, which </span><span class="tx" style="top:294pt;left:0pt;padding-bottom:0.38em;padding-right:1.03em;">can be life threatening. Consequently, diagnostic </span><span class="tx" style="top:308pt;left:0pt;padding-bottom:0.38em;">and pathogen-detection devices will be key enabling </span><span class="tx" style="top:322pt;left:0pt;padding-bottom:0.38em;padding-right:1.64em;">technologies for disease management; the future </span><span class="tx" style="top:336pt;left:0pt;padding-bottom:0.38em;padding-right:1.61em;">accuracy of molecular diagnostics has the power </span><span class="tx" style="top:350pt;left:0pt;padding-bottom:0.38em;padding-right:1.98em;">to transform medicine. The targets of molecular </span><span class="tx" style="top:364pt;left:0pt;padding-bottom:0.38em;padding-right:0.86em;">diagnostics include genetic information on disease </span><span class="tx" style="top:378pt;left:0pt;padding-bottom:0.38em;">presence or predisposition, and the ability to monitor </span><span class="tx" style="top:392pt;left:0pt;padding-bottom:0.38em;padding-right:0.21em;">the physical manifestation of a disease. One enabling </span><span class="tx" style="top:406pt;left:0pt;padding-bottom:0.38em;">technology, DNA sequencing, is advancing rapidly with </span><span class="tx" style="top:420pt;left:0pt;padding-bottom:0.38em;padding-right:0.16em;">some techniques currently capable of reading a human </span><span class="tx" style="top:434pt;left:0pt;padding-bottom:1.78em;padding-right:13.11em;">genome for about $1,000.</span><span class="tx" style="top:462pt;left:0pt;padding-bottom:0.38em;padding-right:3.55em;">Molecular diagnostic devices will revolutionize </span><span class="tx" style="top:476pt;left:0pt;padding-bottom:0.38em;padding-right:2.13em;">medicine by providing a rapid means of testing for </span><span class="tx" style="top:490pt;left:0pt;padding-bottom:0.38em;padding-right:0.16em;">both genetic and pathogenic diseases during surgeries. </span><span class="tx" style="top:504pt;left:0pt;padding-bottom:0.38em;padding-right:1.72em;">Readily available genetic testing will hasten disease </span><span class="tx" style="top:518pt;left:0pt;padding-bottom:0.38em;padding-right:1.37em;">diagnosis and help physicians decide on the optimal </span><span class="tx" style="top:532pt;left:0pt;padding-bottom:0.38em;">treatment for each patient. Such personalized medicine </span><span class="tx" style="top:546pt;left:0pt;padding-bottom:0.38em;padding-right:2.9em;">will reduce the health-care costs associated with </span><span class="tx" style="top:560pt;left:0pt;padding-bottom:0.38em;padding-right:0.93em;">physicians&#8217; prescribing ineffective drugs. In addition, </span><span class="tx" style="top:574pt;left:0pt;padding-bottom:0.38em;padding-right:3.65em;">the declining cost of such testing will facilitate </span><span class="tx" style="top:588pt;left:0pt;padding-bottom:0.38em;padding-right:2.33em;">the cataloguing of many more individuals&#8217; genetic </span><span class="tx" style="top:602pt;left:0pt;padding-bottom:0.38em;padding-right:1.75em;">pro<span style="width:0.58em;">fi</span>les, which will lead to a greater understanding </span><span class="tx" style="top:616pt;left:0pt;padding-bottom:0.38em;padding-right:1.75em;">of the genetic basis of many diseases. Theranostics, </span><span class="tx" style="top:630pt;left:0pt;padding-bottom:0.05em;padding-right:2.48em;">the combination of a diagnostic and a therapeutic </span><br /></div>
</div>
</body>
